6 news items
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
NKTX
13 Jun 24
for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous
HC Wainwright & Co. Maintains Buy on Nkarta, Raises Price Target to $23
NKTX
13 May 24
HC Wainwright & Co. analyst Emily Bodnar maintains Nkarta (NASDAQ:NKTX) with a Buy and raises the price target from $22 to $23.
Needham Maintains Buy on Nkarta, Lowers Price Target to $13
NKTX
13 May 24
Needham analyst Gil Blum maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price target from $15 to $13.
Canaccord Genuity Maintains Buy on Nkarta, Lowers Price Target to $15
NKTX
10 May 24
Canaccord Genuity analyst Bill Maughan maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price target from $16 to $15.
Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing
IPSC
NKTX
11 Apr 24
) unveiled plans to expand clinical development for its lead program, CNTY-101, a CD19-targeting iNK cell therapy, into additional
k907dghrf21drdc963d9z5e4l5k
NKTX
10 Apr 24
Needham analyst Gil Blum reiterates Nkarta (NASDAQ:NKTX) with a Buy and maintains $15 price target.
- Prev
- 1
- Next